BioCryst Pharmaceuticals (BCRX)
(Delayed Data from NSDQ)
$7.52 USD
-0.33 (-4.20%)
Updated Jul 29, 2024 04:00 PM ET
After-Market: $7.51 -0.01 (-0.13%) 7:58 PM ET
1-Strong Buy of 5 1
F Value C Growth F Momentum F VGM
BioCryst Pharmaceuticals (BCRX) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Upside to Average Price Target |
---|---|---|---|
$14.00 | $30.00 | $6.00 | 78.34% |
Price Target
Based on short-term price targets offered by 11 analysts, the average price target for BioCryst Pharmaceuticals comes to $14.00. The forecasts range from a low of $6.00 to a high of $30.00. The average price target represents an increase of 78.34% from the last closing price of $7.85.
Analyst Price Targets (11)
Broker Rating
BioCryst Pharmaceuticals currently has an average brokerage recommendation (ABR) of 1.50 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by 12 brokerage firms. The current ABR compares to an ABR of 1.50 a month ago based on 12 recommendations.
Of the 12 recommendations deriving the current ABR, eight are Strong Buy and two are Buy. Strong Buy and Buy respectively account for 66.67% and 16.67% of all recommendations. A month ago, Strong Buy made up 66.67%, while Buy represented 16.67%.
Broker Rating Breakdown
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 8 | 8 | 8 | 8 | 8 |
Buy | 2 | 2 | 2 | 2 | 2 |
Hold | 2 | 2 | 2 | 2 | 2 |
Sell | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 |
ABR | 1.50 | 1.50 | 1.50 | 1.50 | 1.50 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
7/23/2024 | Piper Sandler | Christopher Raymond | Strong Buy | Strong Buy |
5/7/2024 | Not Identified | Not Identified | Moderate Buy | Moderate Buy |
5/7/2024 | JMP Securities | Jonathan Wolleben | Strong Buy | Strong Buy |
5/7/2024 | H.C. Wainwright & Co. | Andrew S Fein | Strong Buy | Strong Buy |
4/10/2024 | Needham & Company | Serge Belanger | Moderate Buy | Moderate Buy |
4/1/2024 | Cowen & Co. | Stacy Ku | Strong Buy | Strong Buy |
3/19/2024 | Evercore Partners | Liisa A Bayko | Strong Buy | Strong Buy |
2/27/2024 | Not Identified | Not Identified | Hold | Hold |
2/26/2024 | Not Identified | Not Identified | Strong Buy | Strong Buy |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 1.50 |
ABR (Last week) | 1.50 |
# of Recs in ABR | 12 |
Average Target Price | $14.00 |
LT Growth Rate | 40.40% |
Industry | Medical - Drugs |
Industry Rank by ABR | 97 of 252 |
Current Quarter EPS Est: | -0.19 |